GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » Financial Strength

Chordate Medical Holding AB (OSTO:CMH) Financial Strength : 0 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB Financial Strength?

Chordate Medical Holding AB has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Chordate Medical Holding AB did not have earnings to cover the interest expense. Chordate Medical Holding AB's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.00. As of today, Chordate Medical Holding AB's Altman Z-Score is -1.68.


Competitive Comparison of Chordate Medical Holding AB's Financial Strength

For the Medical Devices subindustry, Chordate Medical Holding AB's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordate Medical Holding AB's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's Financial Strength distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's Financial Strength falls into.



Chordate Medical Holding AB Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Chordate Medical Holding AB's Interest Expense for the months ended in Dec. 2023 was kr-0.01 Mil. Its Operating Income for the months ended in Dec. 2023 was kr-10.01 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil.

Chordate Medical Holding AB's Interest Coverage for the quarter that ended in Dec. 2023 is

Chordate Medical Holding AB did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Chordate Medical Holding AB's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 1.928
=0.00

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Chordate Medical Holding AB has a Z-score of -1.68, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -1.68 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chordate Medical Holding AB  (OSTO:CMH) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Chordate Medical Holding AB has the Financial Strength Rank of 0.


Chordate Medical Holding AB Financial Strength Related Terms

Thank you for viewing the detailed overview of Chordate Medical Holding AB's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Chordate Medical Holding AB (OSTO:CMH) Business Description

Traded in Other Exchanges
Address
c/o Regus, Kistagangen 20B, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines